Correlation between ovarian chocolate cyst and serum carbohydrate antigen 125 level and the effect of ultrasound-guided interventional sclerotherapy on serum carbohydrate antigen 125 level

Si-Ming Wang, Siming Wang, Huaiqiu Cai, Huai-Qiu Cai, Xiao‐Qiu Dong, Xiao-Qiu Dong, Qiu‐Lan Fan, Qiu-Lan Fan, Lulu Wang, Lu-Lu Wang, Xiao-Hui Shao, Xiao‐Hui Shao, Li-Wei Zhang, Liwei Zhang
Journal of Obstetrics and Gynaecology Research · 2014 · vol. 41(1) , pp. 92–98 · doi:10.1111/jog.12491 · PMID:25159825 · W1603338560
Other OA: closed CC0 ⤵ 13 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Ovarian chocolate cyst CA-125 levels correlate with disease duration, dysmenorrhea, cyst diameter, and wall thickness, and ultrasound-guided sclerotherapy significantly reduces elevated CA-125 levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: This study was to investigate the correlation between ovarian chocolate cysts and serum carbohydrate antigen (CA)-125 levels and to demonstrate the effect of ultrasound-guided interventional sclerotherapy (UGIS) on serum CA-125 levels. METHODS: Based on the serum CA-125 level, as determined by chemiluminescence detection prior to UGIS, 105 patients with ovarian chocolate cysts were divided into the normal group (CA-125 ≤ 35 U/mL, 45 patients) and the abnormal group (35 U/mL < CA-125 ≤ 200 U/mL, 60 patients). There were six clinical indicators including age, disease duration, dysmenorrhea history, child-bearing history, abortion history and surgical history. The ultrasonography characteristics were cyst diameter, cyst wall thickness and the side on which the cyst occurred. The correlations between serum CA-125 levels pretreatment and the clinical indicators and ultrasonography characteristics was analyzed. The serum CA-125 levels pretreatment, 3 months post-treatment and 6 months post-treatment were compared. RESULTS: The pretreatment serum CA-125 levels of the 105 patients positively correlated with disease duration (r = 0.3932, P = 0.0040), dysmenorrhea history (r = 0.2351, P = 0.0111), cyst diameter (r = 0.3415, P < 0.0001) and cyst wall thickness (r = 0.4263, P < 0.0001). Compared with the pretreatment level, the mean serum CA-125 level in the abnormal group at 3 months post-treatment was significantly lower (P < 0.01), and at 6 months post-treatment, the mean serum CA-125 level had decreased to a normal level (P < 0.01). CONCLUSION: UGIS significantly decreased abnormal serum CA-125 levels in patients with ovarian chocolate cysts.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

MeSH descriptors

CA-125 Antigen Membrane Proteins Ovarian Cysts Ovarian Cysts Sclerotherapy Adolescent Adult CA-125 Antigen Female Humans Membrane Proteins Middle Aged Ovarian Cysts Ultrasonography, Interventional Young Adult

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (32)

Cited by (12)

Source provenance

openalex
last seen: 2026-05-10T11:14:57.310873+00:00
pubmed
last seen: 2026-10-08T21:14:18.823929+00:00
unpaywall
last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0 · commercial use OK